Drs O'Donoghue and McGuire discuss the data on the various SGLT2 inhibitors and GLP1 receptor agonists and when to consider prescribing them to your patients with diabetes.

Drs Cohen and O'Donoghue review new data from the COMPASS and RE-DUAL PCI trials and potential strategies for patients who need anticoagulation and antiplatelet therapy.

Drs Piña and Udelson survey the latest knowledge on the markers and methods to predict patient outcomes.

Dr Allen discusses his study on the use of high-quality decision aids in patients considering left ventricular assist device destination therapy and the wider implications for interventional medicine.

In this annual tradition, Drs Harrington and Gibson discuss their picks for the top cardiology trials of the year, covering PCSK9 inhibitors, anti-inflammatory and anthithrombotic drugs, and PCI.

Noninvasive VT ablation, Riata leads, NOAC/DOAC therapies, HDL-C and infection risk, and fibrosis in triathletes are discussed in this week's podcast.

Dr Mandrola discusses the surprising inverse relationship between quality measures and heart failure mortality with study author Dr Larry Allen.

Drs DeMaria and Piña discuss the meeting of the International Society of Cardiovascular Translational Research at TCT 2017 and the importance of patient-reported outcomes.

Mobile ECGs, PFO closure for migraine, AF care, lytic and mechanical removal of VTE and the PSCK9 inhibitor evolocumab are discussed in this week's podcast.

The American Heart Association sessions featured two new analyses from the FOURIER trial, which prompted a discussion on the cost-effectiveness of PCSK9 inhibitor lipid-lowering therapy.